Covid-19 News

  • By non-infectious do you mean not caused by a virus?


    "Noninfectious diseases are not caused by disease causing organisms or pathogens. These diseases are caused instead from genetic, lifestyle or the environment. Some good examples of these diseases include Cancer, Cardiovascular Disease and Diabetes."

    not disease causing

    we're talking dna fragments that may be old or other

  • Small pharma try to change the rules by which Bigpharma play..

    They want override the patent to make Remdesivir..

    not much to do with the efficacy... just the money..


    "An application for emergency approval, which is being construed as a compulsory license, could override the patent and open up production to other companies,

    who do not have existing tie-ups with Gilead.

    This would help in easing the drug's availability, and help bring prices down."

    https://health.economictimes.i…e-key-covid-drug/82023375

  • They want override the patent to make Remdesivir..

    Are they nuts? Reproducing crap for making criminal money??


    There is no study that shows any use of the Gilead crap. The so called positive result they presented is a consequence of faked data. It had never been a confirmed study target. The only question is how many millions they hat to shift into the FDI reviewers pocket for allowing the cheating.

  • I don't see how that could be. The numbers would not agree with other numbers, such as hospital admissions, deaths, excess deaths for the year, and so on. Also, doctors and others would surely notice such a gigantic discrepancy.


    There are always false positives and false negatives in tests of this nature. There is always a margin of error. But researchers and doctors are careful to measure these things as best they can. They realize that false positives are a problem and must be estimated. They must be accounted for. An 80% false positive rate would make the test useless. People would see that. Most patients who took the test, got a positive result, and self-quarantined would report back to the doctor that nothing happened. They never developed any symptoms. There would be no antibodies in their bloodstream. The doctors would realize the test is not working.

    The people that tested positive were sent home, to convalesce. No more testing unless the symptoms get worse and they go to hospital. How would staff notice, they are treating infected people while false positive sits home for 2 weeks and goes back to work. Catching this at the hospital level is impossible.

  • Regeneron to request FDA clearance to use Covid antibody drug as a preventative treatment


    https://www.cnbc.com/amp/2021/…eventative-treatment.html


    Regeneron Pharmaceuticals said it will ask the FDA to allow its Covid-19 antibody therapy to be used as a preventative treatment.

    The company said in a phase three clinical trial the drug reduced the risk of symptomatic infections in individuals by 81%.

    The drug is already authorized to treat adults with mild-to-moderate Covid-19 and pediatric patients at least 12 years of age who have tested positive for the virus and are at high risk of severe disease.

  • Biomechanical characterization of SARS-CoV-2 spike RBD and human ACE2 protein-protein interaction


    https://www.sciencedirect.com/…cle/pii/S0006349521001417


    Abstract

    The current COVID-19 pandemic has led to a devastating impact across the world. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (the virus causing COVID-19) is known to use the receptor-binding domain (RBD) at viral surface spike (S) protein to interact with the angiotensin-converting enzyme 2 (ACE2) receptor expressed on many human cell types. The RBD-ACE2 interaction is a crucial step to mediate the host cell entry of SARS-CoV-2. Recent studies indicate that the ACE2 interaction with the SARS-CoV-2 S protein has a higher affinity than its binding with the structurally identical S protein of SARS-CoV-1, the virus causing the 2002–2004 SARS outbreak. However, the biophysical mechanism behind such binding affinity difference is unclear. This study utilizes combined single-molecule force spectroscopy and steered molecular dynamics (SMD) simulation approaches to quantify the specific interactions between SARS-CoV-2 or SARS-CoV-1 RBD and ACE2. Depending on the loading rates, the unbinding forces between SARS-CoV-2 RBD and ACE2 range from 70 to 105 pN and are 30–40% higher than those of SARS-CoV-1 RBD and ACE2 under similar loading rates. SMD results indicate that SARS-CoV-2 RBD interacts with the N-linked glycan on Asn90 of ACE2. This interaction is mostly absent in the SARS-CoV-1 RBD-ACE2 complex. During the SMD simulations, the extra RBD-N-glycan interaction contributes to a greater force and prolonged interaction lifetime. The observation is confirmed by our experimental force spectroscopy study. After removing N-linked glycans on ACE2, its mechanical binding strength with SARS-CoV-2 RBD decreases to a similar level of the SARS-CoV-1 RBD-ACE2 interaction. Together, the study uncovers the mechanism behind the difference in ACE2 binding between SARS-CoV-2 and SARS-CoV-1 and could help develop new strategies to block SARS-CoV-2 entry.


    It should be noted that the current models utilize only RBD out of trimeric SARS-CoV-2 S protein and the N-glycan core structure for all N-glycans. Having a fully glycosylated SARS-CoV-2 S protein and ACE2 models would provide further insight into the RBD-ACE2 interactions. With a recently modeled fully glycosylated SARS-CoV-2 S protein model (62) and recently determined glycosylation patterns of ACE2 (63), we plan to study the RBD-ACE2 interactions in a more realistic model.


    In conclusion, the study shows that the biomechanical parameters are important for RBDCoV1 and RBDCoV2 to attach to host cells. Our results suggest important viral-host cell interaction through ACE2 Asn90-glycan. Nonetheless, the potential effect of ACE2 Asn90-glycan on the transmission of COVID-19 remains to be further investigated.

  • Covid variant from South Africa was able to ‘break through’ Pfizer vaccine in Israeli study


    https://www.cnbc.com/amp/2021/…ine-in-israeli-study.html


    The researchers found the prevalence of the variant from South Africa, known as B.1.351, among patients who received two doses of the vaccine was about eight times higher than those who were unvaccinated. The data, published online over the weekend, suggest the B.1.351 is better able to "break through" the protection of the vaccine than the original strain, the researchers wrote in the study.


    "Based on patterns in the general population, we would have expected just one case of the South African variant, but we saw eight," Professor Adi Stern, who headed the research, told The Times of Israel. "We can say it's less effective, but more research is needed to establish exactly how much."


    CNBC has reached out to Pfizer for comment on the study.


    The new data comes as public health officials grow concerned that highly contagious variants, which studies have shown can reduce the effectiveness of vaccines, could stall the world's progress on the pandemic.


    Last month, CDC Director Dr. Rochelle Walensky issued a dire warning, telling reporters that she worried the United States is facing "impending doom" as variants spread and daily Covid-19 cases begin to rebound once again, threatening to send more people to the hospital.



    "I'm going to pause here, I'm going to lose the script, and I'm going to reflect on the recurring feeling I have of impending doom," she said March 29. "We have so much to look forward to, so much promise and potential of where we are and so much reason for hope, but right now I'm scared."


    Israel launched its national vaccination campaign in December prioritizing people 60 and older, health-care workers, and people with comorbid conditions. By February, it was leading the world in vaccinations, inoculating millions of its citizens against the virus.


    In January, Pfizer and the Israeli Ministry of Health entered into a collaboration agreement to monitor the real-world impact of its vaccine.


    The researchers noted the main caveat of the study was the sample size. B.1.351 only made up about 1% of all Covid-19 cases, they said. B.1.1.7, the variant first identified in the U.K., is more prevalent.


    As variants spread, drugmakers said they are testing whether a third dose would offer more protection.


    In February, Pfizer and BioNTech said they were testing a third dose of their Covid-19 vaccine to better understand the immune response against new variants of the virus.

  • Variability in digestive and respiratory tract Ace2 expression is associated with the microbiome


    https://journals.plos.org/plos…1371/journal.pone.0248730


    Abstract

    COVID-19 (coronavirus disease 2019) patients exhibiting gastrointestinal symptoms are reported to have worse prognosis. Ace2 (angiotensin-converting enzyme 2), the gene encoding the host protein to which SARS-CoV-2 spike proteins bind, is expressed in the gut and therefore may be a target for preventing or reducing severity of COVID-19. Here we test the hypothesis that Ace2 expression in the gastrointestinal and respiratory tracts is modulated by the microbiome. We used quantitative PCR to profile Ace2 expression in germ-free mice, conventional raised specific pathogen-free mice, and gnotobiotic mice colonized with different microbiota. Intestinal Ace2 expression levels were significantly higher in germ-free mice compared to conventional mice. A similar trend was observed in the respiratory tract. Intriguingly, microbiota depletion via antibiotics partially recapitulated the germ-free phenotype, suggesting potential for microbiome-mediated regulation of Ace2 expression. Variability in intestinal Ace2 expression was observed in gnotobiotic mice colonized with different microbiota, partially attributable to differences in microbiome-encoded proteases and peptidases. Together, these data suggest that the microbiome may be one modifiable factor determining COVID-19 infection risk and disease severity.

  • and the vaccination rate is about 86%,, not including the macaques.

    In Gibraltar all vulnerable are possibly dead already. They had a very high death rate and almost no more cases since 2 months - looks like without vaccination already...

    Looks like they soon can start again to import south America cocaine without violating quarantine rules...

    Regeneron Pharmaceuticals said it will ask the FDA to allow its Covid-19 antibody therapy to be used as a preventative treatment.

    The company said in a phase three clinical trial the drug reduced the risk of symptomatic infections in individuals by 81%.

    It's interesting how pharma gate tries to generate money with halve way working treatments. Ivermectin gives you a 99.9% protection at virtually no cost less than a coffee in a month. Ivermectin is well known and understood and has almost no risk profile.

    For me all these folks simply are killers as even if they can save a few lives they kill the other 20%.

  • No more testing unless the symptoms get worse and they go to hospital. How would staff notice, they are treating infected people while false positive sits home for 2 weeks and goes back to work. Catching this at the hospital level is impossible.

    The people I know who got COVID-19 were in close communication with their doctors and hospitals until they got better, even after they went home. If 80% of them turned out not to have it, and if they were later found to have no antibodies, I am sure the doctors and hospitals would realize that. That many false positives would severely hamper efforts to control the pandemic. It would make testing useless. Testing was, in fact, largely useless at first because it took too long to obtain results. Doctors were upset about this, and talked about it a lot in the mass media. They would not have remained silent if false positives were as high as 80%, making the testing regime worse than useless.


    Also, as I said, the numbers would not begin to add up. You would have to have millions of other false negatives to make up for the known total cases. That is, cases that were diagnosed by doctors from symptoms. Or, you would have to have millions of people treated for COVID-19 at hospitals and by doctors who were somehow never tested at all. The latter scenario is impossible. After May 2020 enough tests were available to be sure everyone in the hospital or doctor's office with symptoms was tested. Heck, I was tested before surgery when there was no reason to think I had it. Every single patient scheduled for surgery mid-year was tested. If 80% of the uninfected group (the majority) had been false positives, the whole surgery unit would shut down for lack of patients. Didn't happen. Couldn't happen.

  • Trial site update


    External Content youtu.be
    Content embedded from external sources will not be displayed without your consent.
    Through the activation of external content, you agree that personal data may be transferred to third party platforms. We have provided more information on this in our privacy policy.

  • Mike Yeadon...a BigPharma insider

    TM 25:36

    fda medicines and healthcare regulatory authority in the uk and the european..agency.japan as well

    they all said that since these variant vaccines/top up vaccines are so similar to the parent vaccines

    we will not be asking the sponsors the manufacturers for any clinical safety studies


    TM 28:39
    yeah i have a serious problem with the universal vaccination

    with exploratory vaccines is is just

    unbelievably reckless and i'm i'm angry every day

    TM 36:14
    because it's there's no chance of benefits if you're 25 and healthy

    no prior conditions uh you're not at risk from this virus you're not going to

    die you might get a little bit ill not going gonna die and so

    why would you risk giving you knowseveral million

    young women of that description this thing for which we don't have adequate

    safety data we've got about two and ahalf months of formal data

    External Content www.youtube.com
    Content embedded from external sources will not be displayed without your consent.
    Through the activation of external content, you agree that personal data may be transferred to third party platforms. We have provided more information on this in our privacy policy.




  • Media Censored COVID-19 Early Treatment Options

    The Indian media seems to march to a different drum..from the "West"

    Ivermectin is uncensored...

    . When asked about the decision to continue the usage of the drug for the treatment of COVID-19, Dr Surya Kant Tripathi – Head, Respiratory Medicine Department, King George Medical University, Lucknow – told Financial Express Online that Ivermectin is being used both for the treatment of coronavirus patients and as prophylaxis for COVID-19 for more than nine months without any major side effects being reported.


    https://www.financialexpress.c…-drug-has-to-say/2231596/

  • Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study


    https://www.thelancet.com/jour…-3099(21)00170-5/fulltext


    Findings

    Of 496 patients with samples positive for SARS-CoV-2 on PCR and who met inclusion criteria, 341 had samples that could be sequenced. 198 (58%) of 341 had B.1.1.7 infection and 143 (42%) had non-B.1.1.7 infection. We found no evidence of an association between severe disease and death and lineage (B.1.1.7 vs non-B.1.1.7) in unadjusted analyses (prevalence ratio [PR] 0·97 [95% CI 0·72–1·31]), or in analyses adjusted for hospital, sex, age, comorbidities, and ethnicity (adjusted PR 1·02 [0·76–1·38]). We detected no B.1.1.7 VOC-defining mutations in 123 chronically shedding immunocompromised patients or in 32 remdesivir-treated patients. Viral load by proxy was higher in B.1.1.7 samples than in non-B.1.1.7 samples, as measured by cycle threshold value (mean 28·8 [SD 4·7] vs 32·0 [4·8]; p=0·0085) and genomic read depth (1280 [1004] vs 831 [682]; p=0·0011).

    Interpretation

    Emerging evidence exists of increased transmissibility of B.1.1.7, and we found increased virus load by proxy for B.1.1.7 in our data. We did not identify an association of the variant with severe disease in this hospitalised cohort

  • FDA halts j&j vaccine after people develop blood clots


    Thread

    See new Tweets

    Tweet

    U.S. FDA

    @US_FDA

    ·

    20m

    Today FDA and

    @CDCgov

    issued a statement regarding the Johnson & Johnson #COVID19 vaccine. We are recommending a pause in the use of this vaccine out of an abundance of caution.

    U.S. FDA

    @US_FDA

    ·

    20m

    As of 4/12, 6.8m+ doses of the J&J vaccine have been administered in the U.S. CDC & FDA are reviewing data involving 6 reported U.S. cases of a rare & severe type of blood clot in individuals after receiving the vaccine. Right now, these adverse events appear to be extremely rare

    U.S. FDA

    @US_FDA

    ·

    20m

    Treatment of this specific type of blood clot is different from the treatment that might typically be administered.